Avid Bioservices Inc (CDMO)

[biopharm]

I can promise that and ex Omeros Clark E Tedford can't even deny the protein pathways that PROVE PS Targeting required

Omeros goes public for very first time making it clear that tareting of Phosphatidylserine is required

Sept 10, 2019 ...goes public PS Targeting

Nov 20, 2019 ...conference presentation

Dec 4, 2019 ...surrogate Biomarkers based on PS Targeting

Furthermore, the discovery that PS itself stimulates an immunosuppressive GPCR namely GPR174 on all lymphocytes represents a significant advancement in our understanding of how PS regulates tumor immunity.

..
...
Relevance of Findings

Omeros findings are also particularly relevant for patients resistant to checkpoint inhibitors, such as anti-PD-1 (e.g., Keytruda and Opdivo) and anti-CTLA-4 (Yervoy), and to emerging cellular therapies such as CAR-T cells and adoptive T-cell therapy. Checkpoint inhibitors are only effective in a minority of patients, and high levels of adenosine-generating molecules have been observed in non-responding patients. Furthermore, overcoming natural immunosuppression in solid tumors represents a major hurdle for cellular therapies. Because PS and adenosine are both products of cell stress and death in solid tumors, it is expected that patients resistant to checkpoint inhibitors or cellular therapies would benefit greatly from the combined inhibition of the GPR174 and adenosine pathways.
...
“Our team’s discovery of the GPR174-controlled cancer-immunity pathways and their interrelationships with the adenosine pathway have been methodically elucidated and defined,” said Gregory A. Demopulos, M.D., Omeros’ chairman and chief executive officer. “Simply put, Omeros has discovered that there are two feet on the cAMP brake pedal restraining immunity against the tumor and, to enable effective tumor-killing activity, both GPR174 and the adenosine pathway must be inhibited. We are optimizing our small-molecule GPR174 inhibitors with the objective of moving orally available therapeutics into the clinic as rapidly as possible. We look forward to providing physicians and patients with a new and broadly applicable option in cancer immunotherapy.”

Omeros is preparing a manuscript for publication detailing its GPR174-related discoveries and data and plans to present these same discoveries and data beginning this year at upcoming oncology international congresses.
....
....

________________

Full article below:

Omeros Discovers New Cancer-Immunity Pathways Controlled by GPR174

Published: Sep 10, 2019

https://www.biospace.com/article/releases/omeros-discovers-new-cancer-immunity-pathways-controlled-by-gpr174/

____


Nov 20, 2019

OMEROS’ NEW GPR174 IMMUNO-ONCOLOGY DATA PRESENTED AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH CONFERENCE IN BOSTON

....
....
GPR174, a novel target in immuno-oncology that modulates a new cancer immunity axis recently discovered by Omeros. Small-molecule inhibitors of GPR174 are part of Omeros’ proprietary G protein-coupled receptor (GPCR) platform through which it controls 54 new GPCR drug targets and their corresponding compounds. The company also exclusively possesses a novel antibody-generating platform.
...
____

Dec 4, 2019

All of a sudden ....Omeros has surrogate MOS endpoints and FDA allows to have modified the primary and secondary endpoints ....and all this just after they went public re: PS Targeting

https://endpts.com/eager-to-tout-pivotal-win-omeros-however-keeps-key-parameters-shrouded/#
____

I will say this ....the fog will be cleared soon and does Ampersand Capital truly have Avid Bioservices CDMO shareholders in their best interest ?

_____

Catherine Mackey may not even have Avid CDMO in her best interest....especially with the latest PS Targeting based patents this past week at Cour Pharmaceuticals...David Getts etc but this will be another post